1
|
Okuda H, Fukushima H, Nakatsukasa T, Yamamoto K, Kaizaki-Mitsumoto A, Numazawa S, Kamijo Y. Fatal poisoning due to ingestion of boiled oleander leaf extract. J Forensic Sci 2024; 69:351-354. [PMID: 37753820 DOI: 10.1111/1556-4029.15393] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 09/07/2023] [Accepted: 09/14/2023] [Indexed: 09/28/2023]
Abstract
Nerium oleander is an ornamental evergreen shrub belonging to the family Apocynaceae. The Apocynaceae family includes the attractive evergreen shrub known as oleander. The cardiotoxic glycoside, oleandrin, is present in all portions of the common oleander plant. Oleander consumption can result in deadly situations accidentally or as a suicide attempt. After consuming kettle-boiled oleander leaf extract as part of a suicide attempt, an 80-year-old man was discovered comatose in his home and taken to our emergency room. The patient's heart rate was 30 beats per minute, and he had hypotension. Arterial blood gas analysis revealed remarkable metabolic acidosis and hyperkalemia (K: 7.7 mEq/L). An electrocardiogram showed a wide QRS wave, similar to a sine curve. The patient collapsed following cardiac arrest soon after hospital arrival. Veno-arterial extracorporeal membrane oxygenation was initiated; however, the patient eventually died. The serum level of oleandrin at hospital arrival, subsequently measured by LC-MS/MS, was found to be 33.4 ng/mL, far above the levels reported in previous fatal cases.
Collapse
Affiliation(s)
- Hirozumi Okuda
- Department of Emergency and Critical Care Medicine, Nara Medical University, Kashihara City, Nara, Japan
| | - Hidetada Fukushima
- Department of Emergency and Critical Care Medicine, Nara Medical University, Kashihara City, Nara, Japan
| | - Tomoaki Nakatsukasa
- Department of Emergency and Critical Care Medicine, Nara Medical University, Kashihara City, Nara, Japan
| | - Koji Yamamoto
- Department of Emergency and Critical Care Medicine, Nara Medical University, Kashihara City, Nara, Japan
| | - Asuka Kaizaki-Mitsumoto
- Department of Pharmacology, Toxicology, and Therapeutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan
| | - Satoshi Numazawa
- Department of Pharmacology, Toxicology, and Therapeutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan
| | - Yoshito Kamijo
- Department of Clinical Toxicology, Saitama Medical University, Iruma-gun, Saitama, Japan
| |
Collapse
|
2
|
Kaneko S, Ito K, Yuki S, Harada K, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Tsuji Y, Ando T, Kato K, Wakabayashi T, Kotaka M, Takahashi Y, Sakata Y, Komatsu Y. P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Yoshikawa A, Ito K, Yuki S, Kawamoto Y, Saito R, Yamamura T, Yagisawa M, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Sakata Y, Komatsu Y. P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Ito K, Yuki S, Nakano S, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Tateyama M, Sogabe S, Matsumoto R, Sakata Y, Komatsu Y. P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Kazama K, Nakamura M, Tanaka R, Ojima H, Makiyama A, Matsuhashi N, Kagawa Y, Okuda H, Asayama M, Yuasa Y, Negoro Y, Mushiake H, Manaka D, Oba K, Yoshino T, Yoshida K, Maehara Y, Yamazaki K, Oki E, Takahashi T. JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 2019; 30:259-265. [PMID: 30508156 DOI: 10.1093/annonc/mdy526] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The objective of this randomized phase II trial was to evaluate efficacy and safety of the therapeutic sequence of regorafenib followed by cetuximab, compared with cetuximab followed by regorafenib, as the current standard sequence for metastatic colorectal cancer patients. PATIENTS AND METHODS Patients with KRAS exon 2 wild-type metastatic colorectal cancer after failure of fluoropyrimidine, oxaliplatin, and irinotecan were randomized to receive sequential treatment with regorafenib followed by cetuximab ± irinotecan (R-C arm), or the reverse sequence [cetuximab ± irinotecan followed by regorafenib (C-R arm)]. The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) with initial treatment (PFS1), PFS with second treatment (PFS2), safety, and quality of life. Exploratory end points included serial biomarker analyses, including oncogenic alterations from circulating tumor DNA or multiple serum or plasma proteins. RESULTS One-hundred one patients were randomized and eligible for efficacy analysis. Sequential treatment was successful in 86% patients in both arms. Median OS for R-C and C-R was 17.4 and 11.6 months, respectively (P = 0.0293), with a hazard ratio (HR) of 0.61 for OS [95% confidence interval (CI) 0.39-0.96]. The HR for PFS1 (regorafenib in R-C versus cetuximab in C-R) was 0.97 (95% CI 0.61-1.54), and PFS2 (C in R-C versus R in C-R) was 0.29 (95% CI 0.17-0.50). No unexpected safety signals were observed. The quality of life scores during the entire treatment period was not significantly different between the two arms. Circulating biomarker analyses showed emerging oncogenic alterations in RAS, BRAF, EGFR, HER2, and MET, which were more commonly detected after cetuximab than after regorafenib. CONCLUSIONS The therapeutic sequence of regorafenib followed by cetuximab suggests a longer OS than the current standard sequence.
Collapse
Affiliation(s)
- K Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - T Yamanaka
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan
| | - T Denda
- Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan
| | - Y Tsuji
- Department of Medical Oncology, Tonan Hospital, Sapporo, Japan
| | - K Shinozaki
- Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan
| | - Y Komatsu
- Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan
| | - Y Kobayashi
- Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan
| | - J Furuse
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan
| | - H Okuda
- Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan
| | - M Asayama
- Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
| | - K Akiyoshi
- Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan
| | - Y Kagawa
- Department of Surgery, Kansai Rosa Hospital, Amagasaki, Japan
| | - T Kato
- Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - E Oki
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - T Ando
- School of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Y Hagiwara
- Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - Y Ohashi
- Department of Integrated Science and Engineering for Sustainable Society, Faculty of Science and Engineering, Chuo University, Tokyo, Japan
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
| |
Collapse
|
7
|
Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Iwanaga I, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Ito Y, Taketomi A, Hirano S, Sakamoto N, Komatsu Y. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Tsuji Y, Yuki S, Sawada K, Muranaka T, Kobayashi Y, Okuda H, Ogawa K, Minami S, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Saitoh S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Masuishi T, Suzuki T, Sukawa Y, Imamura C, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Kanai T, Takaishi H. Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Kawakami T, Yamazaki K, Oki E, Shimokawa M, Takahashi N, Yokota M, Tokunaga S, Esaki T, Gamoh M, Maeda A, Tsuji Y, Sakai A, Hatanaka K, Shimada Y, Shiozawa M, Komatsu Y, Okuda H, Ohue M, Maehara Y. Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Nakamura M, Komatsu Y, Muranaka T, Yagisawa M, Kawamoto Y, Nakatsumi H, Yuki S, Saiki T, Ishiguro A, Tateyama M, Kobayashi Y, Miyagishima T, Takahata T, Sato A, Dazai M, Okuda H, Fujikawa K, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y. HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Yoshino T, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Yuki S, Komatsu Y, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Shinohara T, Miyashita K, Ito Y, Taketomi A, Hirano S, Sakamoto N. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Soda T, Miyagawa Y, Ueda N, Takezawa K, Okuda H, Fukuhara S, Fujita K, Kiuchi H, Uemura M, Okamoto Y, Tsujimura A, Tanaka H, Nonomura N. Systematic characterization of human testis-specific actin capping protein β3 as a possible biomarker for male infertility. Hum Reprod 2018; 32:514-522. [PMID: 28104696 DOI: 10.1093/humrep/dew353] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2016] [Accepted: 12/16/2016] [Indexed: 11/13/2022] Open
Abstract
STUDY QUESTION Is actin capping protein (CP) β3 involved in human spermatogenesis and male infertility? SUMMARY ANSWER Human CPβ3 (hCPβ3) is expressed in testis, changes its localization dynamically during spermatogenesis, and has some association with male infertility. WHAT IS KNOWN ALREADY The testis-specific α subunit of CP (CPα3) was previously identified in human, and mutations in the cpα3 gene in mouse were shown to induce malformation of the sperm head and male infertility. However, CPβ3, which is considered to be a heterodimeric counterpart of CPα3, has been neither characterized in human nor reported in association with male infertility. STUDY DESIGN, SIZE, DURATION To confirm the existence of CPβ3 in human testis, fresh semen samples from proven fertile men were analyzed. To investigate protein expression during spermatogenesis, cryopreserved testis obtained from men with obstructive azoospermia were examined by immunofluorescent analysis. To assess the association of CP with male infertility, we compared protein expression of human CPα3 (hCPα3) and hCPβ3 using immunofluorescent analysis of cryopreserved sperm between men with normozoospermia (volunteers: Normo group, n = 20) and infertile men with oligozoospermia and/or asthenozoospermia (O + A group, n = 21). PARTICIPANTS/MATERIALS, SETTING, METHODS The tissue-specific expression of hCPβ3 was investigated by RT-PCR and Western blot analysis. To investigate whether hCPα3 and hCPβ3 form a heterodimer, a tandem expression vector containing hcpα3 tagged with monomeric red fluorescent protein 1 and hcpβ3 tagged with enhanced green fluorescent protein in a single plasmid was constructed and analyzed by co-immunoprecipitation (Co-IP) assay. The protein expression profiles of hCPα3 and hCPβ3 during spermatogenesis were examined by immunohistochemical analysis using human spermatogenic cells. The protein expressions of hCPα3 and hCPβ3 in sperm were compared between the Normo and O + A groups by immunohistochemical analysis. MAIN RESULTS AND THE ROLE OF CHANCE RT-PCR showed that mRNA of hcpβ3 was expressed exclusively in testis. Western blot analysis detected hCPβ3 with anti-bovine CPβ3 antibody. Co-IP assay with recombinant protein showed that hCPα3 and hCPβ3 form a protein complex. At each step during spermatogenesis, the cellular localization of hCPβ3 changed dynamically. In spermatogonia, hCPβ3 showed a slight signal in cytoplasm. hCPβ3 expression was conspicuous mainly from spermatocytes, and hCPβ3 localization dynamically migrated from cytoplasm to the acrosomal cap and acrosome. In mature spermatozoa, hCPβ3 accumulated in the postacrosomal region and less so at the midpiece of the tail. Double-staining analysis revealed that hCPα3 localization was identical to hCPβ3 at every step in the spermatogenic cells. Most spermatozoa from the Normo group were stained homogenously by both hCPα3 and hCPβ3. In contrast, significantly more spermatozoa in the O + A versus Normo group showed heterogeneous or lack of staining for either hCPα3 or hCPβ3 (abnormal staining) (P < 0.001). The percentage of abnormal staining was higher in the O + A group (52.4 ± 3.0%) than in the Normo group (31.2 ± 2.5%). Even by confining the observations to morphologically normal spermatozoa selected in accordance with David's criteria, the percentage of abnormal staining was still higher in the O + A group (39.9 ± 2.9%) versus the Normo group (22.5 ± 2.1%) (P < 0.001). hCPβ3 in conjunction with hCPα3 seemed to play an important role in spermatogenesis and may be associated with male infertility. LARGE SCALE DATA Not applicable. LIMITATIONS REASONS FOR CAUTION Owing to the difficulty of collecting fresh samples of human testis, we used cryopreserved samples from testicular sperm extraction. To examine the interaction of spermatogenic cells or localization in seminiferous tubules, fresh testis sample of healthy males are ideal. WIDER IMPLICATIONS OF THE FINDINGS The altered expression of hCPα3 and hCPβ3 may not only be a cause of male infertility but also a prognostic factor for the results of ART. They may be useful biomarkers to determine the fertilization ability of human sperm in ART. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (JP16K20133). The authors declare no competing interests.
Collapse
Affiliation(s)
- T Soda
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - Y Miyagawa
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - N Ueda
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - K Takezawa
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - H Okuda
- Monash Biomedicine Discovery Institute and Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria 3800, Australia
| | - S Fukuhara
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - K Fujita
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - H Kiuchi
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - M Uemura
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - Y Okamoto
- Okamoto Clinic, Osaka 558-0004, Japan
| | - A Tsujimura
- Department of Urology, Juntendo University Urayasu Hospital, Urayasu 279-0021, Japan
| | - H Tanaka
- Molecular Biology laboratory, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Nagasaki 859-3298, Japan
| | - N Nonomura
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| |
Collapse
|
17
|
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y. First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Miyagishima T, Yuki S, Muranaka T, Tsuji Y, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Sakata Y, Komatsu Y. Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of regorafenib for patients with metastatic colorectal cancer: HGCSG1401. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Affiliation(s)
- H. Okuda
- Princeton University, Plasma Physics Laboratory, Princeton, New Jersey 08540
| |
Collapse
|
22
|
Sasaki T, Yuki S, Kawamoto Y, Harada K, Meguro T, Miyagishima T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. 190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00348-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
23
|
Sasaki T, Yuki S, Kawamoto Y, Harada K, Meguro T, Miyagishima T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. 190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Sukawa Y, Nosho K, Miura Y, Takano T, Ito M, Yonesaka K, Mori M, Tokunaga S, Kawada J, Okuda H, Sakamoto T, Hirashima Y, Uchino K, Miyata Y, Yoshimura K, Yamazaki K, Hironaka S, Boku N, Hyodo I, Muro K. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Yuki S, Komatsu Y, Muranaka T, Harada K, Sugiyama J, Tsuji Y, Ando T, Hosokawa A, Hatanaka K, Naruse H, Takahata T, Sato A, Kobayashi Y, Miyagishima T, Okuda H, Kudo M, Nakamura M, Hisai H, Sakamoto N, Sakata Y. Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Miyagishima T, Yuki S, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Kobayashi Y, Sasaki T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. P-152 Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Hosokawa A, Yuki S, Kawamoto Y, Ando T, Muto O, Nakamura M, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Hayashi H, Fujikawa K, Kudo M, Honda T, Sakata Y, Komatsu Y. 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Dazai M, Yuki S, Muranaka T, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Ohta T, Sato A, Eto K, Onodera K, Sato Y, Kato K, Nakamura M, Muto O, Ishiguro A, Tateyama M, Okuda H, Sakata Y, Komatsu Y. 158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Komatsu Y, Yuki S, Nakatsumi H, Sawada K, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato K, Okuda H, Sogabe S, Miyagishima T, Miyashita K, Sakamoto N, Sakata Y. 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y. 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Nakatsumi H, Yuki S, Kawamoto Y, Muranaka T, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Sakamoto N, Komatsu Y. 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31014-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Kobayashi Y, Yuki S, Kawamoto Y, Sawada K, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Tagaki T, Hisai H, Koike M, Abe R, Sakata Y, Komatsu Y. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31016-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Hatanaka K, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Okuda H, Kudo M, Sakata Y, Komatsu Y. P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Yuki S, Komatsu Y, Muranaka T, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Kawamoto Y, Yoshizaki K, Sato A, Eto K, Onodera K, Kato S, Nakamura M, Muto O, Abe M, Sato Y, Ishiguro A, Tateyama M, Okuda H, Sakamoto N, Sakata Y. P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report-. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Shibata Y, Matsuoka H, Munemoto Y, Bando H, Nishimura G, Ogata Y, Okuda H, Nakamura M, Terada I, Uchida H, Shiroiwa T, Kishimoto J, Maeda K. P-247 A follow-up results of team management approach for XELOX therapy in patients with advanced/recurrent colorectal cancer: the SMILE Study (Study of Metastatic colorectal cancer to investigate Impact of Learning Effect). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Nakamura M, Kobayashi Y, Yuki S, Nakatsumi H, Hayashi H, Iwanaga I, Tsuji Y, Hatanaka K, Okuda H, Konno J, Yamamoto F, Iwai K, Onodera M, Takagi T, Hisai H, Koike M, Abe R, Oba K, Sakata Y, Komatsu Y. Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Third Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer: Hgcsg1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-Stepp): Additional Analysis of Qol and Skin Toxicity. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Muto O, Yuki S, Nakamura M, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. First Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Fukushima H, Yuki S, Nakatsumi H, Hayashi H, Harada K, Muranaka T, Nakamura M, Kawamoto Y, Kobayashi Y, Sogabe S, Miyagishima T, Tateyama M, Eto K, Hatanaka K, Ishiguro A, Okuda H, Takahashi Y, Iwanaga I, Sakata Y, Komatsu Y. Randomized Phase Ii Trial of Hange-Shasin-To Versus Placebo to Prevent Diarrhea in Patients with Metastatic Colorectal Cancer Under Iris+Bev Second-Line Treatment (Hgcsg1301). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.73] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene 2014; 34:3452-62. [PMID: 25174399 PMCID: PMC4345161 DOI: 10.1038/onc.2014.277] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 07/01/2014] [Accepted: 07/19/2014] [Indexed: 12/18/2022]
Abstract
We previously characterized the link between WNT7A and the progression of ovarian cancer. Other groups have identified FGF1 as a relevant risk factor in ovarian cancer. Here, we show a linkage between these two signaling pathways that may be exploited to improve treatment and prognosis of patients with ovarian cancer. High expression of WNT7A and FGF1 are correlated in ovarian carcinomas and poor overall patient survival. A chromatin immunoprecipitation assay demonstrated that WNT7A/β-catenin signaling directly regulates FGF1 expression via TCF binding elements in the FGF1-1C promoter locus. In vitro gene manipulation studies revealed that FGF1 is sufficient to drive the tumor promoting effects of WNT7A. In vivo xenograft studies confirmed that the stable overexpression of WNT7A or FGF1 induced a significant increase in tumor incidence, while FGF1 knockdown in WNT7A overexpressing cells caused a significant reduction in tumor size. Niclosamide most efficiently abrogated WNT7A/β-catenin signaling in our model, inhibited β-catenin transcriptional activity and cell viability, and increased cell death. Furthermore, niclosamide decreased cell migration following an increase in E-cadherin subsequent to decreased levels of SLUG. The effects of niclosamide on cell functions were more potent in WNT7A overexpressing cells. Oral niclosamide inhibited tumor growth and progression in an intraperitoneal xenograft mouse model representative of human ovarian cancer. Collectively, these results indicate that FGF1 is a direct downstream target of WNT7A/β-catenin signaling and this pathway has potential as a therapeutic target in ovarian cancer. Moreover, niclosamide is a promising inhibitor of this pathway and may have clinical relevance.
Collapse
Affiliation(s)
- M L King
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| | - M E Lindberg
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| | - G R Stodden
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| | - H Okuda
- Laboratory for Malignancy Control Research, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - S D Ebers
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| | - A Johnson
- Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Chicago Medical Center, Chicago, IL, USA
| | - A Montag
- Department of Pathology, The University of Chicago Medical Center, Chicago, IL, USA
| | - E Lengyel
- Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Chicago Medical Center, Chicago, IL, USA
| | - J A MacLean Ii
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| | - K Hayashi
- Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA
| |
Collapse
|
41
|
Sato Y, Yuki S, Kobayashi Y, Okuda H, Tsuji Y, Naruse H, Koike M, Meguro T, Nakamura M, Komatsu Y. Retrospective Cohort Study on the Safety and Efficacy of PMAB for MCRC Patients : Analysis of Clinical Early Predictor. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Saito M, Kaneto H, Okuda H, Kodaira J, Hagiwara T, Kozawa H, Yoshimoto M, Yamashita K, Arimura Y, Shinomura Y. Serum HER2 in Gastric Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Kubota K, Kadomura T, Ohta K, Koyama K, Okuda H, Kobayashi M, Ishii C, Fujiwara Y, Nishiora T, Ohmae Y, Ohmae T, Kitajima M. Analyses of laboratory data and establishment of reference values and intervals for healthy elderly people. J Nutr Health Aging 2012; 16:412-6. [PMID: 22499467 DOI: 10.1007/s12603-011-0355-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVE Protein-energy malnutrition is a common disorder in the elderly. Although serum albumin is commonly used as a nutritional marker, data is lacking on serum albumin levels in the elderly. The purpose of this study was to determine whether serum albumin levels decrease with advancing age and to establish reference value and interval of laboratory data for elderly people (75 years and over). PARTICIPANTS Blood samples from 13821 healthy people, 42064 outpatients, and 15959 inpatients were collected during 2008. Blood from 127 of our nutrition support team (NST) patients was also collected during August 2006 and May 2009, and analyzed. MEASUREMENTS Serum albumin, hemoglobin, total cholesterol levels and lymphocyte count were determined. We analyzed the change in each parameter in accordance with age, compared the data for elderly people with younger people, and established new reference values. Clinical outcomes were examined depending on the improved reference values. RESULTS Albumin was lower in older persons than in younger persons. The estimated reference value and interval were 42 (48-36) g/l in older persons and was much lower in NST patients. Hemoglobin was decreased while cholesterol and lymphocyte count were not changed in older persons: all were markedly decreased in NST patients. Terms of hospital stay were significantly longer and mortality rates were significantly higher in older persons, comparing from above to below using a new reference value of albumin (36 g/l). CONCLUSIONS The serum albumin level decreases with advancing age, but it was maintained to some extent in healthy older people. Serum albumin levels related to the clinical outcome. Hemoglobin and cholesterol levels and lymphocyte count were all lower in NST patients. These measurements may be valuable markers of nutritional status and can help in guiding the need for nutritional support.
Collapse
Affiliation(s)
- K Kubota
- Nutrition Support Team and Department of Gastroenterological Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Terai H, Miwa K, Okuda H, Tazaki Y, Suzuki T, Kojima K, Morita J, Maehigashi A, Takeda K. Multi-platform experiment to cross a boundary between laboratory and real situational studies: experimental discussion of cross-situational consistency of driving behaviors. Work 2012; 41 Suppl 1:1471-6. [PMID: 22316924 DOI: 10.3233/wor-2012-0340-1471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
We constructed an innovative experimental platform to study cross-situational consistency in driving behavior, conducted behavioral experiments, and reported the data obtained in the experiment. To discuss cross-situational consistency, we separated situations in which people use some systems to conduct tasks into three independent conceptual factors: environment, context, and system. We report the experimental results with the following systems: a laboratory system with a gaming controller and steering/pedal controllers and a real system, COMS an instrumented vehicle. The results are summarized as follows. 1) The individual behaviors in each system were stable, and consistency was retained. 2) The consistency of the behaviors was also confirmed when the participants drove using different interfaces in identical systems. 3) However, only slight correlation was observed across different systems in a specific situation where a strong high-order cognitive constraint (i.e., rapid driving) and a weak low-order cognitive constraint (driving with easy handling toward a straight-line course) were given.
Collapse
Affiliation(s)
- H Terai
- Graduate School of Information Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abdo W, Kakizoe Y, Ryono M, Dover SR, Fukushi H, Okuda H, Kano R, Shibahara T, Okada E, Sakai H, Yanai T. Pulmonary zygomycosis with Cunninghamella bertholletiae in a killer whale (Orcinus orca). J Comp Pathol 2011; 147:94-9. [PMID: 22000035 DOI: 10.1016/j.jcpa.2011.08.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Revised: 08/08/2011] [Accepted: 08/29/2011] [Indexed: 11/29/2022]
Abstract
An adult female killer whale (Orcinus orca) was transported to the Port of Nagoya public aquarium in June 2010. While the animal was being maintained in the aquarium there was a gradual decrease in body weight. On October 1st, 2010 the whale exhibited signs of gastrointestinal disease and died on January 14th, 2011. At necropsy examination the gastric compartments were filled with a large number of variably-sized rocks (total weight 81.4 kg) and there was marked ulceration in the third compartment. There were multifocal tubercle-like nodules within the lungs and on sectioning there were numerous abscesses and pulmonary cavities. Microscopically, there was severe suppurative pneumonia associated with fungal hyphae that were infrequently septate and often branched. Numerous bacterial colonies were also present. The hyphae demonstrated immunohistochemical cross-reactivity with Rhizomucor spp. and Cunninghamella bertholletiae was cultured. Bacteriological culture revealed the presence of Proteus mirabilis, Pseudomonas aeruginosa and Pseudomonas oryzihabitans. This case represents the first documentation of zygomycosis associated with C. bertholletiae in a marine mammal.
Collapse
Affiliation(s)
- W Abdo
- Department of Veterinary Pathology, Faculty of Applied Biological Science, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Sukawa Y, Goto A, Okuda H, Suzuki K, Hasegawa Y, Yonezawa K, Abe T, Shinomura Y. Unexplained melena associated with a history of endovascular stent grafting of abdominal aortic aneurysms: aortoduodenal fistula. Endoscopy 2009; 41 Suppl 2:E84. [PMID: 19370524 DOI: 10.1055/s-0029-1214484] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- Y Sukawa
- Department of Gastroenterology and Rheumatology, Kushiro City General Hospital, Kushiro City, Japan
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Taguchi K, Noriyuki T, Furonaka O, Kuroda Y, Akimoto E, Kuranishi F, Nakahara M, Fukuda T, Ishizaki Y, Okuda H, Hashimoto M, Yonehara S. [Metastatic lung cancer origin from osteosarcoma of mandible invading tracheal lumen]. Kyobu Geka 2009; 62:571-574. [PMID: 19588829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 52-year-old woman underwent the surgical treatment for osteosarcoma of the left mandible in 2003 and was followed up afterward. She suffered from dry cough and bloody sputum, and was admitted to our hospital in April 2007. Computed tomography (CT) revealed several nodules in bilateral lung, and bronchofiberscopy showed the endobronchial tumor obstructing in the right main bronchus. The metastatic tumor progressed in the right main bronchus from the right S6 lung segment. The tumor rapidly progressed in the right bronchus in comparison with the CT findings in about 2 weeks, and the possibility of the tracheal obstruction was considered. She underwent the right middle and lower lobectomy, and the endobronchial tumor was pulled through the right main bronchus. The postoperative course was uneventful, the patient was discharged on 14th postoperative day, and the chemotherapy using cisplatin (CDDP) and adriamycin (ADR) is on-going.
Collapse
Affiliation(s)
- K Taguchi
- Department of General Thoracic Surgery, Onomichi General Hospital, Onomichi, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Noriyuki T, Hamamoto M, Takazawa Y, Katoh K, Hashimoto M, Kuranishi F, Nakahara M, Fukuda T, Ishizaki Y, Okuda H, Akimoto E, Yonehara S. [Thymic carcinoma involving aortic arch; report of a case]. Kyobu Geka 2009; 62:417-421. [PMID: 19425386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Adenocarcinoma of the thymus is a very rare malignant tumor. The standard treatment for advanced thymic carcinoma has not yet been established, and the prognosis is poor. We report a case of thymic carcinoma that involving the aortic arch and the innominate vein. A 78-year-old woman was admitted to our hospital complaining of hoarseness in April 2007. The computed tomography (CT) scan showed an anterior mediastinal tumor contiguous to the aortic arch and the innominate vein with swelling lymphnodes. Microspcopic examinations of specimens obtained by CT-guided needle biopsy revealed poorly differenciated adenocarcinoma. The carcinoembryonic antigen (CEA) level of serum elevated at 54.9 ng/ml. Thymic carcinoma was diagnosed. The chemoradiotherapy [concurrent, carboplatin (CBDCA) + paclitaxel(TXL)-->vinorelbine (NVB), 60 Gy] was performed, but the effect of the therapy was limited. The resection of the tumor with a part of aortic arch and other peripheral tissues was performed in Augast 2007. The postoperative course was uneventful and the CEA level of serum lowered to the normal. She was discharged 30 days after surgery.
Collapse
Affiliation(s)
- Toshio Noriyuki
- Department of General Thoracic Surgery, Onomichi General Hospital, Onomichi, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Okuda H, Nakajima K, Fujiwara K, Morishita K, Ochiai S. Two-dimensionally curved Ge for focusing crystals prepared by a hot plastic deformation. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
50
|
|